dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Nowotny, Hanna |
dc.contributor.author | Neumann, Uta |
dc.contributor.author | Tardy-Guidollet, Véronique |
dc.contributor.author | Ahmed, S. Faisal |
dc.contributor.author | Baronio, Federico |
dc.contributor.author | Battelino, Tadej |
dc.contributor.author | Yeste Fernandez, Diego |
dc.date.accessioned | 2022-07-21T07:31:37Z |
dc.date.available | 2022-07-21T07:31:37Z |
dc.date.issued | 2022-03-23 |
dc.identifier.citation | Nowotny H, Neumann U, Tardy-Guidollet V, Ahmed SF, Baronio F, Battelino T, et al. Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe. Eur J Endocrinol. 2022 Mar 23;186(5):K17–K24. |
dc.identifier.issn | 1479-683X |
dc.identifier.uri | https://hdl.handle.net/11351/7889 |
dc.description | Dexametasona; Prenatal |
dc.description.sponsorship | This work was supported by the Deutsche Forschungsgemeinschaft (Heisenberg Professorship, 325768017 to N R and 314061271-TRR205 to N R and A H), the European Commission for funding EndoERN CHAFEA FPA grant no. 739527, the Eva Luise und Horst Köhler Stiftung & Else Kröner-Fresenius-Stiftung (2019_KollegSE.03 to H N) and the Stockholm County Council (Senior clinical research fellowship dnr RS 2019-1140 to S L), Stiftelsen Frimurare Barnhuset i Stockholm and Lisa and Johan Grönbergs Stiftelse. |
dc.language.iso | eng |
dc.publisher | BioScientifica |
dc.relation.ispartofseries | European Journal of Endocrinology;186(5) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Hiperplàsia - Tractament |
dc.subject | Malalties congènites - Tractament |
dc.subject.mesh | Adrenal Hyperplasia, Congenital |
dc.subject.mesh | /drug therapy |
dc.title | Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1530/EJE-21-0554 |
dc.subject.decs | hiperplasia suprarrenal congénita |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.1530/EJE-21-0554 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Nowotny H] Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany. [Neumann U] Centre for Chronic Sick Children, Department of Paediatric Endocrinology and Diabetology, Charité Universitätsmedizin Berlin, Berlin, Germany. [Tardy-Guidollet V] Laboratoire de Biochimie et Biologie Moléculaire, Hospices Civils de Lyon, Centre National de Référence ‘Développement Génital: du fœtus à l’adulte DEV-GEN’ Université Lyon I, Lyon, France. [Ahmed SF] Developmental Endocrinology Research Group, University of Glasgow, Glasgow, UK. [Baronio F] Paediatric Endocrinology Unit, Department of Medical and Surgical Sciences, S.Orsola-Malpighi University Hospital, Bologna, Italy. [Battelino T] Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, University Children’s Hospital, Ljubljana, Slovenia. [Yeste D] Servei d’Endocrinologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERER, ISCIII, Madrid, Spain |
dc.identifier.pmid | 35235536 |
dc.identifier.wos | 000802046600004 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |